Inclusion Criteria:

        Group A: Primary therapy subjects will be included in the study if they meet all of the
        following general criteria:

          1. Male or female ≥ 14 - 90 years of age. If female of child-bearing potential and
             outside of the window of 10 days since the first day of the last menstrual period, a
             negative pregnancy test is required.

          2. Presence of somatostatin receptor positive tumour(s) (either histologically or
             Octreoscan image proven), with at least 1 tumour site reliably evaluable by CT or MRI
             of at least 1.5 cm (smallest dimension) with respect to RECIST criteria (the target
             lesion).

          3. Presence of somatostatin receptors on (at least) the target lesion demonstrated by
             uptake of OctreoScan® at least equal to liver uptake within 12 weeks of enrollment.

          4. Life expectancy greater than 26 weeks from enrollment.

          5. Serum creatinine ≤ 130 μmol/L, and a measured glomerular filtration rate (GFR) using
             plasma clearance of ≥50 mL/min measured within 2 weeks of enrollment.

          6. Haemoglobin concentration ≥ 90 g/L; white blood cell count (WBC) ≥ 3 x 109/L;
             platelets ≥ 100 x 109/L measured within 2 weeks of enrollment.

          7. Liver function tests (serum albumin, total bilirubin, alanine amniotransferase
             (ALT),aspartate aminotransferase (AST) and alkaline phosphatase) ≤ 3 X the limit of
             normal.

          8. Eastern Cooperative Oncology Group (ECOG) Performance Scale Score ≤ 2 measured within
             2 weeks of enrollment.

          9. Provide written informed consent prior to enrollment.

         10. Ki 67 < 20%, unless patients has been treated with chemotherapy and lesions are stable
             (Ki 67 < 30%)

        Group B: Secondary therapy subjects will be included in the study if they meet all of the
        following general criteria:

          1. Male or female ≥ 14 - 90 years of age. If female of child-bearing potential and
             outside of the window of 10 days since the first day of the last menstrual period, a
             negative pregnancy test is required.

          2. Have received Lu-DOTA-TATE treatment at the London Health Sciences Centre under the
             Special Access Programed or other radionuclide therapy for neuroendocrine tumor.

          3. Provide written informed consent prior to enrollment.

        Exclusion Criteria:

        Group A: Primary therapy subjects will be excluded from the study if they meet any of the
        following criteria:

          1. Potential for surgery with curative intent. Local surgery for symptomatic relief
             permitted as long as target lesion unaffected.

          2. Surgery, radiation therapy, radioisotope therapy, change in Sandostatin LAR therapy
             dosage, cytotoxic chemotherapy, embolization or other investigative therapy
             [interferons, mammalian target of rapamycin (mTOR) inhibitors] within 12 weeks of
             enrollment. Localized external beam irradiation permitted as long as target lesion
             unaffected.

          3. Known brain metastases unless these metastases have been treated or stable (confirmed
             by CT) for ≥ 6 months prior to enrollment

          4. Uncontrolled diabetes mellitus defined as fasting glucose ≥ 3 X the upper limit of
             normal within 12 weeks of enrollment.

          5. Another significant medical, psychiatric or surgical condition uncontrolled by
             treatment, which may interfere with completion or conduct of the study (such as
             urinary incontinence, co-existing malignancies).

          6. Pregnancy.

          7. Breast feeding.

          8. Prior radiation therapy to more than 25% of the bone marrow.

        Group B: Secondary therapy subjects will be excluded from the study if they meet any of the
        following criteria:

          1. Another significant medical, psychiatric or surgical condition uncontrolled by
             treatment, which may interfere with completion or conduct of the study (such as
             urinary incontinence, co-existing malignancies).

          2. Pregnancy.

          3. Breast feeding.